Skip to search formSkip to main contentSkip to account menu

PR-104

Known as: PR104 
A non-toxic, small-molecule, hypoxia-activated, 3,5-dinitrobenzamide nitrogen mustard pre-prodrug with potential antitumor activity. Upon intravenous… 
National Institutes of Health

Related topics

Related topics

2 relations
DNA

Broader (1)

Nitrogen Mustard Compounds

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Therapeutic journery of nitrogen mustard as alkylating anticancer agents: Historic to future perspectives.
Highly Cited
2015
Highly Cited
2015
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia
We previously demonstrated vast expansion of hypoxic areas in the leukemic microenvironment and provided a rationale for using… 
Review
2014
Review
2014
Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia
Hypoxia, a state of low oxygen, is a common feature of solid tumors and is associated with disease progression as well as… 
Highly Cited
2011
Highly Cited
2011
Pronounced Hypoxia in Models of Murine and Human Leukemia: High Efficacy of Hypoxia-Activated Prodrug PR-104
Recent studies indicate that interactions between leukemia cells and the bone marrow (BM) microenvironment promote leukemia cell… 
Highly Cited
2011
Highly Cited
2011
A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients
BackgroundThe phosphate ester PR-104 is rapidly converted in vivo to the alcohol PR-104A, a nitrogen mustard prodrug that is… 
Review
2010
Review
2010
The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3.
PR-104, currently in phase II clinical trials, is a phosphate ester pre-prodrug which is converted in vivo to its cognate alcohol… 
Highly Cited
2010
Highly Cited
2010
A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors
PurposePR-104 is a “pre-prodrug” designed to be activated to a dinitrobenzamide nitrogen mustard cytotoxin by nitroreduction in… 
Highly Cited
2007
Highly Cited
2007
Mechanism of Action and Preclinical Antitumor Activity of the Novel Hypoxia-Activated DNA Cross-Linking Agent PR-104
Purpose: Hypoxia is a characteristic of solid tumors and a potentially important therapeutic target. Here, we characterize the… 
Highly Cited
2007
Highly Cited
2007
Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia.
Highly Cited
2007
Highly Cited
2007
Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)